IL86751A - Pharmaceutical preparations containing cyclosporins and cyclosporins of various kinds - Google Patents

Pharmaceutical preparations containing cyclosporins and cyclosporins of various kinds

Info

Publication number: IL86751A
Authority: IL; Israel
Prior art keywords: residue; cyclosporin; cyclosporins; mebmt; ciclosporin
Prior art date: 1987-06-17

Application number

IL8675188A

Other languages

English (en)

Hebrew (he)

Other versions

IL86751A0 (en

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-06-17

Filing date

1988-06-15

Publication date

1994-02-27

1987-06-17 Priority claimed from GB878714118A external-priority patent/GB8714118D0/en

1987-06-17 Priority claimed from GB878714119A external-priority patent/GB8714119D0/en

1987-06-17 Priority claimed from GB878714125A external-priority patent/GB8714125D0/en

1987-06-17 Priority claimed from GB878714093A external-priority patent/GB8714093D0/en

1987-06-17 Priority claimed from GB878714115A external-priority patent/GB8714115D0/en

1987-06-17 Priority claimed from GB878714090A external-priority patent/GB8714090D0/en

1987-06-17 Priority claimed from GB878714100A external-priority patent/GB8714100D0/en

1987-06-17 Priority claimed from GB878714098A external-priority patent/GB8714098D0/en

1988-06-15 Application filed by Sandoz Ag filed Critical Sandoz Ag

1988-11-30 Publication of IL86751A0 publication Critical patent/IL86751A0/xx

1994-02-27 Publication of IL86751A publication Critical patent/IL86751A/en

Links

229930182912 cyclosporin Natural products 0.000 title claims abstract description 337
108010036941 Cyclosporins Proteins 0.000 title claims abstract description 180
239000000203 mixture Substances 0.000 title claims description 11
229960001265 ciclosporin Drugs 0.000 claims description 251
108010036949 Cyclosporine Proteins 0.000 claims description 180
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 178
229930105110 Cyclosporin A Natural products 0.000 claims description 161
125000001183 hydrocarbyl group Chemical group 0.000 claims description 27
229910052799 carbon Inorganic materials 0.000 claims description 21
-1 propyl Ciclosporin Chemical compound 0.000 claims description 18
125000004432 carbon atom Chemical group C* 0.000 claims description 17
125000001931 aliphatic group Chemical group 0.000 claims description 14
239000008194 pharmaceutical composition Substances 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 7
125000004429 atom Chemical group 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 6
125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims description 3
239000003795 chemical substances by application Substances 0.000 claims description 3
239000003085 diluting agent Substances 0.000 claims description 3
230000036457 multidrug resistance Effects 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 1
125000004849 alkoxymethyl group Chemical group 0.000 claims 1
230000000118 anti-neoplastic effect Effects 0.000 abstract description 28
229940034982 antineoplastic agent Drugs 0.000 abstract description 28
239000000824 cytostatic agent Substances 0.000 abstract description 21
238000002560 therapeutic procedure Methods 0.000 abstract description 21
238000004519 manufacturing process Methods 0.000 abstract description 20
238000002512 chemotherapy Methods 0.000 abstract description 11
230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
230000001085 cytostatic effect Effects 0.000 abstract description 10
239000003096 antiparasitic agent Substances 0.000 abstract description 7
239000000543 intermediate Substances 0.000 abstract description 7
239000002260 anti-inflammatory agent Substances 0.000 abstract description 2
229940121363 anti-inflammatory agent Drugs 0.000 abstract description 2
229940125687 antiparasitic agent Drugs 0.000 abstract description 2
229960003444 immunosuppressant agent Drugs 0.000 abstract description 2
239000003018 immunosuppressive agent Substances 0.000 abstract description 2
238000000034 method Methods 0.000 description 80
238000012360 testing method Methods 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 35
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 31
150000001875 compounds Chemical class 0.000 description 31
238000011282 treatment Methods 0.000 description 29
239000002246 antineoplastic agent Substances 0.000 description 27
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 27
238000002360 preparation method Methods 0.000 description 23
125000002252 acyl group Chemical group 0.000 description 21
210000004027 cell Anatomy 0.000 description 21
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
230000035945 sensitivity Effects 0.000 description 21
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 20
238000006243 chemical reaction Methods 0.000 description 20
230000008569 process Effects 0.000 description 20
206010028980 Neoplasm Diseases 0.000 description 19
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
239000007858 starting material Substances 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
230000001965 increasing effect Effects 0.000 description 17
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 16
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical group CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 15
229960001338 colchicine Drugs 0.000 description 15
238000002651 drug therapy Methods 0.000 description 15
239000000243 solution Substances 0.000 description 15
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
239000003814 drug Substances 0.000 description 14
230000001506 immunosuppresive effect Effects 0.000 description 14
239000000741 silica gel Substances 0.000 description 14
229910002027 silica gel Inorganic materials 0.000 description 14
229940079593 drug Drugs 0.000 description 13
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 12
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 12
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 12
229960000975 daunorubicin Drugs 0.000 description 12
201000002491 encephalomyelitis Diseases 0.000 description 12
229940044683 chemotherapy drug Drugs 0.000 description 11
229940088679 drug related substance Drugs 0.000 description 11
229920006395 saturated elastomer Polymers 0.000 description 11
239000000126 substance Substances 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
230000002141 anti-parasite Effects 0.000 description 10
239000000047 product Substances 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
241000700159 Rattus Species 0.000 description 9
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
229940009456 adriamycin Drugs 0.000 description 8
201000011510 cancer Diseases 0.000 description 8
230000000973 chemotherapeutic effect Effects 0.000 description 8
229940035423 ethyl ether Drugs 0.000 description 8
239000012074 organic phase Substances 0.000 description 8
230000009467 reduction Effects 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
206010059866 Drug resistance Diseases 0.000 description 7
206010027476 Metastases Diseases 0.000 description 7
241000699670 Mus sp. Species 0.000 description 7
125000000217 alkyl group Chemical group 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000001747 exhibiting effect Effects 0.000 description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
238000003756 stirring Methods 0.000 description 7
230000004614 tumor growth Effects 0.000 description 7
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 6
208000030852 Parasitic disease Diseases 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
230000000977 initiatory effect Effects 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 6
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 6
229960004528 vincristine Drugs 0.000 description 6
230000009471 action Effects 0.000 description 5
239000008186 active pharmaceutical agent Substances 0.000 description 5
229940041181 antineoplastic drug Drugs 0.000 description 5
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 5
229960005420 etoposide Drugs 0.000 description 5
239000000284 extract Substances 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000004615 ingredient Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 5
229960001278 teniposide Drugs 0.000 description 5
TYFOVYYNQGNDKH-KCLVVAEESA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-33-[(1r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26, Chemical compound CCCCC(C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O TYFOVYYNQGNDKH-KCLVVAEESA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
230000005911 anti-cytotoxic effect Effects 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
231100000433 cytotoxic Toxicity 0.000 description 4
238000010511 deprotection reaction Methods 0.000 description 4
230000006872 improvement Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
235000008390 olive oil Nutrition 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
238000004393 prognosis Methods 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical compound CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
201000009030 Carcinoma Diseases 0.000 description 3
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
125000000676 alkoxyimino group Chemical group 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
239000003904 antiprotozoal agent Substances 0.000 description 3
239000012267 brine Substances 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
229910052736 halogen Inorganic materials 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
201000004792 malaria Diseases 0.000 description 3
239000002207 metabolite Substances 0.000 description 3
238000005949 ozonolysis reaction Methods 0.000 description 3
239000012071 phase Substances 0.000 description 3
229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
102220079670 rs759826252 Human genes 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
235000002906 tartaric acid Nutrition 0.000 description 3
239000011975 tartaric acid Substances 0.000 description 3
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 2
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
208000009386 Experimental Arthritis Diseases 0.000 description 2
206010018910 Haemolysis Diseases 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
AKCRVYNORCOYQT-YFKPBYRVSA-N N-methyl-L-valine Chemical compound CN[C@@H](C(C)C)C(O)=O AKCRVYNORCOYQT-YFKPBYRVSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
206010033799 Paralysis Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
206010070834 Sensitisation Diseases 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
125000006193 alkinyl group Chemical group 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000001093 anti-cancer Effects 0.000 description 2
230000000843 anti-fungal effect Effects 0.000 description 2
230000000078 anti-malarial effect Effects 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
230000000842 anti-protozoal effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000003430 antimalarial agent Substances 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000036765 blood level Effects 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
238000001816 cooling Methods 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
125000001033 ether group Chemical group 0.000 description 2
239000002024 ethyl acetate extract Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
230000008588 hemolysis Effects 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000005457 ice water Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
125000003884 phenylalkyl group Chemical group 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
208000028172 protozoa infectious disease Diseases 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
230000000630 rising effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
201000004409 schistosomiasis Diseases 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
238000010189 synthetic method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
239000012485 toluene extract Substances 0.000 description 2
238000006257 total synthesis reaction Methods 0.000 description 2
RQDKNFDEXBVLPV-GSVOUGTGSA-N (2R)-2-azidobutanoic acid Chemical compound CC[C@@H](N=[N+]=[N-])C(O)=O RQDKNFDEXBVLPV-GSVOUGTGSA-N 0.000 description 1
SYXYUKMELXLDBD-WKHWYDSQSA-N (3s,6r,9s,12s,15s,18s,24s,27s,30s,33s)-24-ethyl-27-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,6,9,13,19,22,28-octamethyl-3,12,18,33-tetrakis(2-methylpropyl)-15,30-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,2 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O SYXYUKMELXLDBD-WKHWYDSQSA-N 0.000 description 1
GBIWPCXWDSDANU-JYFGSSRXSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,18,19,25,28-decamethyl-6,9,24-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,2 Chemical compound CC[C@@H]1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GBIWPCXWDSDANU-JYFGSSRXSA-N 0.000 description 1
GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 1
GNGBSKIQPUCELM-YBAOVNABSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29, Chemical compound CC[C@@H]1NC(=O)[C@H](C[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-YBAOVNABSA-N 0.000 description 1
ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 description 1
AHQFCPOIMVMDEZ-UNISNWAASA-N (e,2s,3r,4r)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical compound CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 1
AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
BMTAFVWTTFSTOG-UHFFFAOYSA-N Butylate Chemical compound CCSC(=O)N(CC(C)C)CC(C)C BMTAFVWTTFSTOG-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
SYXYUKMELXLDBD-UHFFFAOYSA-N Cyclosporin E Natural products CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O SYXYUKMELXLDBD-UHFFFAOYSA-N 0.000 description 1
GNGBSKIQPUCELM-UHFFFAOYSA-N Cyclosporin F Natural products CCC1NC(=O)C(CC(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-UHFFFAOYSA-N 0.000 description 1
TZCUXJXFGWPMBF-UHFFFAOYSA-N Cyclosporin P Natural products CC=CCC(C)C(O)C1NC(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O TZCUXJXFGWPMBF-UHFFFAOYSA-N 0.000 description 1
RVYSEKGVPXFKBH-UHFFFAOYSA-N Cyclosporin V Natural products CCC1NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(CC)NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC1=O RVYSEKGVPXFKBH-UHFFFAOYSA-N 0.000 description 1
FAOPPOYNVNUOHA-UHFFFAOYSA-N Cyclosporin Z Natural products CCCCCCC1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(CC)NC1=O FAOPPOYNVNUOHA-UHFFFAOYSA-N 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
FVIGODVHAVLZOO-UHFFFAOYSA-N Dixanthogen Chemical compound CCOC(=S)SSC(=S)OCC FVIGODVHAVLZOO-UHFFFAOYSA-N 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
208000035126 Facies Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
208000004883 Lipoid Nephrosis Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025538 Malignant ascites Diseases 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
241000224017 Plasmodium berghei Species 0.000 description 1
241000223960 Plasmodium falciparum Species 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
241000219061 Rheum Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
206010070863 Toxicity to various agents Diseases 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000001857 anti-mycotic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000002543 antimycotic Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000008901 benefit Effects 0.000 description 1
USFRYJRPHFMVBZ-UHFFFAOYSA-M benzyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)CC1=CC=CC=C1 USFRYJRPHFMVBZ-UHFFFAOYSA-M 0.000 description 1
230000037396 body weight Effects 0.000 description 1
235000010633 broth Nutrition 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
239000012830 cancer therapeutic Substances 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000007799 cork Substances 0.000 description 1
239000000287 crude extract Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
108010019594 cyclosporin D Proteins 0.000 description 1
108010019252 cyclosporin F Proteins 0.000 description 1
108010019251 cyclosporin H Proteins 0.000 description 1
238000005661 deetherification reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
108010040781 dihydrocyclosporin D Proteins 0.000 description 1
229940043279 diisopropylamine Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
208000014951 hematologic disease Diseases 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
150000002431 hydrogen Chemical group 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
208000020816 lung neoplasm Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
239000000401 methanolic extract Substances 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
NOCGROPYCGRERZ-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 NOCGROPYCGRERZ-UHFFFAOYSA-M 0.000 description 1
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000002969 morbid Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000017095 negative regulation of cell growth Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000003439 radiotherapeutic effect Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
238000012216 screening Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000002023 wood Substances 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)
Hematology (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IL8675188A 1987-06-17 1988-06-15 Pharmaceutical preparations containing cyclosporins and cyclosporins of various kinds IL86751A (en)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
GB878714118A GB8714118D0 (en)	1987-06-17	1987-06-17	Organic compounds
GB878714119A GB8714119D0 (en)	1987-06-17	1987-06-17	Organic compounds
GB878714125A GB8714125D0 (en)	1987-06-17	1987-06-17	Organic compounds
GB878714093A GB8714093D0 (en)	1987-06-17	1987-06-17	Organic compounds
GB878714115A GB8714115D0 (en)	1987-06-17	1987-06-17	Organic compounds
GB878714090A GB8714090D0 (en)	1987-06-17	1987-06-17	Organic compounds
GB878714100A GB8714100D0 (en)	1987-06-17	1987-06-17	Organic compounds
GB878714098A GB8714098D0 (en)	1987-06-17	1987-06-17	Organic compounds

Publications (2)

Publication Number	Publication Date
IL86751A0 IL86751A0 (en)	1988-11-30
IL86751A true IL86751A (en)	1994-02-27

Family

ID=27571252

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8675188A IL86751A (en)	1987-06-17	1988-06-15	Pharmaceutical preparations containing cyclosporins and cyclosporins of various kinds

Country Status (21)

Country	Link
US (1)	US5525590A (de)
EP (1)	EP0296122B1 (de)
JP (2)	JPH0832724B2 (de)
KR (1)	KR970010927B1 (de)
AT (1)	ATE95193T1 (de)
AU (1)	AU614086B2 (de)
CA (1)	CA1338728C (de)
CY (1)	CY1939A (de)
CZ (1)	CZ411791A3 (de)
DE (1)	DE3884470T2 (de)
DK (1)	DK173873B1 (de)
ES (1)	ES2059558T3 (de)
HK (1)	HK152796A (de)
HU (1)	HU211678A9 (de)
IE (1)	IE62482B1 (de)
IL (1)	IL86751A (de)
MY (1)	MY103582A (de)
NZ (1)	NZ225041A (de)
PT (1)	PT87745B (de)
SA (1)	SA97170746A (de)
SK (1)	SK411791A3 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0283801A3 (de) *	1987-03-27	1990-05-30	Abbott Laboratories	Fluoreszenz-Polarisations-Test für Cyclosporin A und Metaboliten und verwandte Immunogene und Antikörper
US5236899A (en) *	1987-11-16	1993-08-17	Merck & Co., Inc.	6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
GB2230440B (en) *	1989-02-09	1993-05-19	Sandoz Ltd	Novel cyclosporin galenic forms
US5540931A (en) *	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
GB8916901D0 (en) *	1989-07-24	1989-09-06	Sandoz Ltd	Improvements in or relating to organic compounds
US5122511A (en) *	1990-02-27	1992-06-16	Merck & Co., Inc.	Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
GB9204466D0 (en) *	1992-03-02	1992-04-15	Sandoz Ltd	Improvements in or relating to organic compounds
GB9208712D0 (en) *	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
SG45449A1 (en) *	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
CZ278863B6 (en) *	1992-09-07	1994-07-13	Galena	Medicinal preparations with n-methylated cyclic undecapeptides
DK0589843T3 (da)	1992-09-25	2002-04-02	Novartis Ag	Cyclosporinholdige farmaceutiske præparater
US20020099067A1 (en) *	1993-07-08	2002-07-25	Ulrich Posanski	Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9318612D0 (en) *	1993-09-08	1993-10-27	Sandoz Ltd	An assay
US6187547B1 (en)	1993-09-08	2001-02-13	Novartis Ag	Assay kit
ES2293638T3 (es) *	1994-03-25	2008-03-16	Isotechnika, Inc.	Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en)	1994-03-25	2002-01-01	Isotechnika, Inc.	Method of using deuterated calcium channel blockers
JP3833248B2 (ja)	1994-11-03	2006-10-11	ノバルティス・アクチエンゲゼルシャフト	簡単な組成及び高い生物有効性を有する経口投与のためのシクロスポリンの新規処方物及びその製造法
GR1002687B (el) *	1995-04-17	1997-05-06	Novartis Ag (Novartis Sa) (Novartis Inc.)	Διαδικασια παραγωγης.
US6395770B1 (en) *	1995-10-26	2002-05-28	Baker Norton Pharmaceuticals, Inc.	Method and compositions for administering taxanes orally to human patients
US6245805B1 (en)	1995-10-26	2001-06-12	Baker Norton Pharmaceuticals, Inc.	Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
GB9601120D0 (en)	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
AU737053B2 (en) *	1997-01-30	2001-08-09	Novartis Ag	Oil-free pharmaceutical compositions containing cyclosporin A
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
DE69840586D1 (de) *	1997-10-08	2009-04-02	Isotechnika Inc	Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
AU748334B2 (en)	1997-10-16	2002-05-30	Board Of Regents, The University Of Texas System	Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
USRE40987E1 (en)	1998-07-01	2009-11-17	Debiopharm S.A.	Cyclosporin with improved activity profile
WO2000040219A1 (en)	1998-12-30	2000-07-13	Dexcel Ltd.	Dispersible concentrate for the delivery of cyclosporin
US6255280B1 (en) *	1999-04-08	2001-07-03	University Of Kentucky Research Foundation	Protection against traumatic brain injury
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
US6784156B2 (en)	2001-03-05	2004-08-31	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of respiratory diseases
GB0113663D0 (en) *	2001-06-05	2001-07-25	Novartis Ag	Use of organic compounds
US20030087813A1 (en)	2001-10-12	2003-05-08	Or Yat Sun	Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en) *	2001-10-12	2004-10-26	Enanta Pharmaceuticals, Inc.	Cyclosporin analogs for the treatment of autoimmune diseases
DK1436322T3 (da) *	2001-10-19	2008-11-03	Isotechnika Inc	Blandinger af cyclosporinanaloger og deres anvendelse som immunmodulerende midler
AU2007221839B2 (en) *	2001-10-19	2011-05-12	Aurinia Pharmaceuticals Inc.	Synthesis of cyclosporin analogs
DE60231570D1 (de) *	2001-10-19	2009-04-23	Isotechnika Inc	Synthese von Cyclosporinanalogen
PT1435910E (pt) *	2001-10-19	2009-09-07	Isotechnika Inc	Novos pré-concentrados de microemulsão de análogos da ciclosporina
US7012065B2 (en)	2003-02-07	2006-03-14	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of immune disorders
AU2004222306A1 (en) *	2003-03-17	2004-09-30	Albany Molecular Research, Inc.	Novel cyclosporins
TW200505946A (en) *	2003-04-08	2005-02-16	Hoffmann La Roche	Process for preparation of cyclosporin a analog
CA2561907A1 (en) *	2004-04-08	2005-10-20	Applied Research Systems Ars Holding N.V.	Composition comprising a jnk inhibitor and cyclosporin
US20060014677A1 (en) *	2004-07-19	2006-01-19	Isotechnika International Inc.	Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
JP2008514702A (ja) *	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	新規シクロスポリン類似体およびそれらの薬学的使用
WO2006039163A2 (en)	2004-09-29	2006-04-13	Amr Technology, Inc.	Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006041631A2 (en) *	2004-10-06	2006-04-20	Amr Technology, Inc.	Novel cyclosporin alkynes and their utility as pharmaceutical agents
BRPI0517207A (pt) *	2004-12-17	2008-09-30	Isotechnika Inc	composto isolado, metabólito isolado de ciclo {{(e)- e (z)- (2s,3r,4r)-3-hidróxi-4-metil-2-(metilamino)-6,8-nonadien oil}-l-2-aminobutiril-n-metil-glicil-n-metil-l-leucil-l-v alil-n-metil-l-leucil-l-alanil-d-alanil-n-metil-l-leucil- n-metil-l-leucil-n-metil-l-valil} (isa247) e os sais e solvatos farmaceuticamente aceitáveis dos mesmos, método de preparação de metabólitos de isa247 in vitro, método de produção de um metabólito hidroxilado de isa247, metabólito hidroxilado isolado de isa247, metabólito hidroxilado isolado, método de produção de um metabólito de epóxido de isa247 in vitro, metabólito isolado de epóxido de isa247, metabólito isolado de epóxido, método de produção de um metabólito de diol de isa247 in vitro, metabólito de diol isolado de isa247, metabólito de diol isolado, método de produção de um metabólito de diol de isa247, método de produção de um metabólito de diol de isa247 e composição farmacêutica
US7696166B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20080206287A1 (en) *	2006-09-18	2008-08-28	Reed John C	Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
RU2462262C2 (ru) *	2007-01-04	2012-09-27	Дебиофарм С А	Неиммуносупрессорный циклоспорин для лечения врожденной миопатии ульриха
TW200932240A (en)	2007-10-25	2009-08-01	Astellas Pharma Inc	Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
AU2009276241A1 (en) *	2008-07-30	2010-02-04	Ciclofilin Pharmaceuticals Corp.	Nonimmunosuppressive cyclosporine analogue molecules
CA2740873C (en)	2008-10-17	2019-09-10	Wisconsin Alumni Research Foundation	Method of making biologically active alpha-beta peptides
CA2748389A1 (en) *	2008-12-31	2010-07-08	Scynexis, Inc.	Derivatives of cyclosporin a
EP2391376A4 (de) *	2009-01-30	2012-08-01	Enanta Pharm Inc	Cyclosporin-analoga zur prävention oder behandlung von hepatitis-c-infektionen
US8481483B2 (en) *	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8349312B2 (en) *	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8367053B2 (en) *	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8685917B2 (en) *	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
DE102009037551A1 (de) *	2009-08-17	2011-02-24	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Cyclosporinderivate
US8623814B2 (en) *	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
WO2011141891A1 (en)	2010-05-12	2011-11-17	Debio Recherche Pharmaceutique S.A.	Use of cycloundecadepsipeptide compounds
LT2651965T (lt)	2010-12-15	2019-01-10	Contravir Pharmaceuticals, Inc.	Ciklosporino analogo molekulės su modifikuotomis 1 ir 3 aminorūgštimis
WO2012145427A1 (en)	2011-04-18	2012-10-26	The Trustees Of Columbia University In The City Of New York	Methods to treat cancer using cyclosporine and cyclosporine derivatives
EP2900684A2 (de)	2012-09-29	2015-08-05	Novartis AG	Cyclische peptide und verwendung als arzneimittel
US8906853B2 (en)	2012-11-28	2014-12-09	Enanta Pharmaceuticals, Inc.	[N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
KR20160045136A (ko)	2013-08-26	2016-04-26	이난타 파마슈티칼스, 인코포레이티드	C형 간염을 예방 또는 치료하기 위한 사이클로스포린 유사체
ES2716685T3 (es)	2014-01-24	2019-06-14	Dana Farber Cancer Inst Inc	Moléculas de anticuerpo para PD-1 y usos de las mismas
TWI777174B (zh)	2014-03-14	2022-09-11	瑞士商諾華公司	針對lag-3之抗體分子及其用途
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es)	2014-10-14	2016-06-01	Novartis Ag	Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016073480A1 (en)	2014-11-03	2016-05-12	Enanta Pharmaceuticals, Inc.	Novel cyclosporin analogues for preventing or treating hepatitis c infection
EP3233918A1 (de)	2014-12-19	2017-10-25	Novartis AG	Kombinationstherapien
CA2979215A1 (en)	2015-03-10	2016-09-15	Aduro Biotech, Inc.	Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EP3316902A1 (de)	2015-07-29	2018-05-09	Novartis AG	Kombinationstherapien mit antikörpermolekülen gegen tim-3
CN108025051B (zh)	2015-07-29	2021-12-24	诺华股份有限公司	包含抗pd-1抗体分子的联合疗法
LT3317301T (lt)	2015-07-29	2021-07-26	Novartis Ag	Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
WO2017027973A1 (en)	2015-08-18	2017-02-23	Novation Pharmaceuticals Inc.	Benzopyran derivatives and uses thereof
SMT202200118T1 (it)	2015-11-03	2022-05-12	Janssen Biotech Inc	Anticorpi che legano specificamente pd-1 e loro usi
ES2986067T3 (es)	2015-12-17	2024-11-08	Novartis Ag	Moléculas de anticuerpos frente a PD-1 y usos de las mismas
WO2018009466A1 (en)	2016-07-05	2018-01-11	Aduro Biotech, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
CN110785187B (zh)	2017-06-22	2024-04-05	诺华股份有限公司	针对cd73的抗体分子及其用途
US12398209B2 (en)	2018-01-22	2025-08-26	Janssen Biotech, Inc.	Methods of treating cancers with antagonistic anti-PD-1 antibodies
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
WO2020014652A1 (en) *	2018-07-13	2020-01-16	New York University	Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
WO2021053559A1 (en)	2019-09-18	2021-03-25	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN114208781B (zh) *	2022-01-20	2022-12-20	河南农业大学	一种抑制草地贪夜蛾龄期的方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4210581A (en) *	1975-11-04	1980-07-01	Sandoz Ltd.	Organic compounds
CH614931A5 (de) *	1975-11-04	1979-12-28	Sandoz Ag
ATE43335T1 (de) *	1980-02-14	1989-06-15	Sandoz Ag	Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
CH667274A5 (de) *	1984-03-23	1988-09-30	Sandoz Ag	Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB8407618D0 (en) *	1984-03-23	1984-05-02	Sandoz Ltd	Organic compounds
EP0194972B1 (de) *	1985-03-11	1992-07-29	Sandoz Ag	Cyclosporine
US4798823A (en) *	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"

1988
- 1988-06-14 EP EP88810403A patent/EP0296122B1/de not_active Expired - Lifetime
- 1988-06-14 ES ES88810403T patent/ES2059558T3/es not_active Expired - Lifetime
- 1988-06-14 AT AT88810403T patent/ATE95193T1/de not_active IP Right Cessation
- 1988-06-14 DE DE88810403T patent/DE3884470T2/de not_active Expired - Lifetime
- 1988-06-15 CA CA000569523A patent/CA1338728C/en not_active Expired - Fee Related
- 1988-06-15 NZ NZ225041A patent/NZ225041A/en unknown
- 1988-06-15 MY MYPI88000662A patent/MY103582A/en unknown
- 1988-06-15 AU AU17679/88A patent/AU614086B2/en not_active Expired
- 1988-06-15 DK DK198803265A patent/DK173873B1/da not_active IP Right Cessation
- 1988-06-15 IE IE180788A patent/IE62482B1/en not_active IP Right Cessation
- 1988-06-15 IL IL8675188A patent/IL86751A/en not_active IP Right Cessation
- 1988-06-16 PT PT87745A patent/PT87745B/pt not_active IP Right Cessation
- 1988-06-16 KR KR1019880007330A patent/KR970010927B1/ko not_active Expired - Fee Related
- 1988-06-16 JP JP63149227A patent/JPH0832724B2/ja not_active Expired - Lifetime
1991
- 1991-12-27 SK SK4117-91A patent/SK411791A3/sk unknown
- 1991-12-27 CZ CS914117A patent/CZ411791A3/cs unknown
1994
- 1994-11-10 US US08/337,346 patent/US5525590A/en not_active Expired - Lifetime
1995
- 1995-06-22 HU HU95P/P00332P patent/HU211678A9/hu unknown
- 1995-08-16 JP JP7208783A patent/JP2772372B2/ja not_active Expired - Lifetime
1996
- 1996-08-08 HK HK152796A patent/HK152796A/en not_active IP Right Cessation
1997
- 1997-03-25 SA SA97170746A patent/SA97170746A/ar unknown
- 1997-05-16 CY CY193997A patent/CY1939A/xx unknown

Also Published As

Publication number	Publication date
HU211678A9 (en)	1995-12-28
SK411791A3 (en)	1995-07-11
IE62482B1 (en)	1995-02-08
DK326588D0 (da)	1988-06-15
CY1939A (en)	1997-05-16
JPH0832724B2 (ja)	1996-03-29
EP0296122A2 (de)	1988-12-21
SA97170746A (ar)	2005-12-03
JP2772372B2 (ja)	1998-07-02
EP0296122B1 (de)	1993-09-29
HK152796A (en)	1996-08-16
PT87745B (pt)	1992-10-30
KR970010927B1 (ko)	1997-07-02
DE3884470D1 (de)	1993-11-04
PT87745A (pt)	1988-07-01
CZ411791A3 (en)	1993-02-17
JPH0848696A (ja)	1996-02-20
DK173873B1 (da)	2002-01-21
IE881807L (en)	1988-12-17
DE3884470T2 (de)	1994-03-10
CA1338728C (en)	1996-11-19
ES2059558T3 (es)	1994-11-16
MY103582A (en)	1993-08-28
US5525590A (en)	1996-06-11
JPS6445396A (en)	1989-02-17
AU614086B2 (en)	1991-08-22
KR890000519A (ko)	1989-03-15
IL86751A0 (en)	1988-11-30
DK326588A (da)	1988-12-18
AU1767988A (en)	1988-12-22
EP0296122A3 (en)	1990-06-20
NZ225041A (en)	1991-03-26
ATE95193T1 (de)	1993-10-15

Legal Events

Date	Code	Title
1997-11-20	HC	Change of name of proprietor(s)
1998-12-06	KB	Patent renewed
2002-08-14	KB	Patent renewed
2008-12-29	EXP	Patent expired

Publication	Publication Date	Title
CA1338728C (en)	1996-11-19	Cyclosporins and their use a pharmaceuticals
US4639434A (en)	1987-01-27	Novel cyclosporins
US4764503A (en)	1988-08-16	Novel cyclosporins
US6710029B1 (en)	2004-03-23	Dehydrodidemnin B
US4914188A (en)	1990-04-03	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
EP0373260B1 (de)	1994-03-09	Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen
US5310726A (en)	1994-05-10	Lipopeptide compounds
US6156724A (en)	2000-12-05	Uses of didemnins as immunomodulating agents
US5386010A (en)	1995-01-31	Lipopeptide compounds
EP0032009A1 (de)	1981-07-15	Derivate cyclischer Peptidkerne
US7348311B2 (en)	2008-03-25	Derivatives of dehydrodidemnin B
AU596071B2 (en)	1990-04-26	Novel cyclosporins
JPH02184699A (ja)	1990-07-19	“８−アミノ酸”に改良のある新規シクロスポリン誘導体
JPH0643322B2 (ja)	1994-06-08	抗真菌剤